Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin - J-LANCELOT

Description:

The goal of the trial was to evaluate treatment with the novel protease-activated receptor-1 (PAR-1) antagonist E5555 (atopaxar) compared with placebo among Japanese patients with an acute coronary syndrome (ACS) or coronary artery disease (CAD). PAR-1 binding inhibits platelet activation.